Curative isosorbide-5-mononitrate treatment, in opposition to the beneficial preventive one, aggravates the prothrombotic and proconstrictor state in cyclosporine-induced hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 8, 2005, Pages 640-648

  Reis, F ^a   Ponte, L ^a   Rocha, L ^a   Teixeira Lemos, E ^a   Almeida, L ^a   Alcobia, T ^a   Lourenco M ^c   Palmeiro, A ^c   Ferrer Antunes, C A ^c   Costa Almeida, C ^b   Teixeira, Frederico ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Arterial hypertension treatment; cGMP; Cyclosporine A; Isosorbide 5 mononitrate; Nitric oxide; Platelet aggregation; Reactive oxygen species; Serotonin; Thromboxane A2 prostacyclin balance

Indexed keywords

ADENOSINE DIPHOSPHATE; CYCLIC GMP; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOSORBIDE 5 NITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOPRONT; PROSTACYCLIN; SEROTONIN; THROMBOXANE A2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ERYTHROCYTE COUNT; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; HYPERTENSION; INTERMETHOD COMPARISON; LIPID PEROXIDATION; MALE; NONHUMAN; PROPHYLAXIS; PROSTAGLANDIN SYNTHESIS; RAT; SEROTONIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ANIMALS; AORTA; BLOOD PLATELETS; CYCLIC GMP; CYCLOSPORINE; EPOPROSTENOL; HYPERTENSION; ISOSORBIDE DINITRATE; LIPID PEROXIDATION; PLATELET ACTIVATION; RATS; RATS, WISTAR; THROMBOXANE A2; VASOCONSTRICTION;

EID: 22644435282     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0305-1870.2005.04244.x     Document Type: Article

References (40)

1. Sander M, Victor RG. Hypertension after cardiac transplantation: Pathophysiology and management. Curr. Opin. Nephrol. Hypertens. 1995; 4: 443-51.
2. Muraki T, Sasaki Y, Gidding JC, Ishii H, Kaneko T, Yamamoto J. Antithrombotic effects of FK506 versus prothrombotic effect of cyclosporine in vivo. Transplantation 1995; 60: 308-9.
3. Cartier R, Dagenais F, Hollmann C, Cambron H, Buluran J. Chronic exposure to cyclosporine affects endothelial and smooth muscle reactivity in the rat aorta. Ann. Thorac. Surg. 1994; 58: 789-94.
4. Reis F, Tavares P, Rito LC et al. Platelet activation is increased in cyclosporin A-induced hypertensive rats. J. Cardiovasc. Pharmacol. 2000; 36: 56-64.
5. Huang LQ, Whitworth JA, Chesterman CN. Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. Blood Coagul. Fibrinolysis 1995; 6: 438-45.
6. Reis F, Tavares P, Fontes-Ribeiro CA, Ferrer-Antunes C, Teixeira F. The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. Thromb. Res. 1999; 96: 365-72.
7. Miller BW, Hmiel SP, Schnitzler MA, Brennan DC. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation. Am. J. Kidney Dis. 1997; 29: 813-14.
8. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab. Invest. 1986; 55: 455-62.
9. Stephan D, Billing A, Krieger JP et al. Endothelium-dependent relaxation in the isolated rat kidney: Impairment by cyclosporine A. J. Cardiovasc. Pharmacol. 1995; 26: 859-68.
10. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail. Rev. 2003; 8: 71-86.
11. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001; 88: 756-62.
12. Chang HR, Lee RP, Wu CY, Chen HI. Nitric oxide in mesenteric vascular reactivity: A comparison between rats with normotension and hypertension. Clin. Exp. Pharmacol. Physiol. 2002; 29: 275-80.
13. Santiago M, Reis F, Almeida L, Alcobia T, Dionísio J, Teixeira F. Impairment of vascular and platelet nitric oxide and 3′,5′-cyclic guanosine monophosphate content in cyclosporin A-induced hypertensive rats. Fundam. Clin. Pharmacol. 2003; 17: 43-50.
14. Akita K, Dusting GJ, Hickey H. Suppression of nitric oxide production by cyclosporin A and FK506A in rat vascular smooth muscle cells. Clin. Exp. Pharmacol. Physiol. 1994; 21: 231-3.
15. Oriji GK, Keiser HR. Role of nitric oxide in cyclosporin A-induced hypertension. Hypertension 1998; 32: 849-55.
16. O'Neil GS, Chester AH, Kushwaha S, Rose M, Tadjkarimi S, Yacoub MH. Cyclosporin treatment does not impair the release of nitric oxide in human coronary arteries. Br. Heart J. 1991; 66: 212-16.
17. Stroes ES, Luscher TF, Groot FG, Koomans HA, Rabelink TJ. Cyclosporin A increases nitric oxide activity in vivo. Hypertension 1997; 29: 570-5.
18. Hansen JM, Johansen NJ, Mollerup HM, Anderson NF, Strandgaard S. Effects of nitric oxide blockade and cyclosporin A on cardiovascular and renal function in normal man. J. Hypertens. 1999; 17: 1707-13.
19. Reis F, Santiago M, Almeida L et al. Isosorbide-5-mononitrate and L-arginine effect on the cyclosporin-induced arterial hypertension and vascular nitric oxide impairment. In: Tooke J, Shore A, Whatmore J (eds). The Microcirculation and Vascular Biology. Monduzzi Editore SpA, Bologna. 2002; 257-61.
20. Reis F, Almeida L, Alcobia T et al. Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3′,5′-monophosphate disturbances. Thromb. Res. 2003; 110: 107-15.
21. 2 generation in rat and human arteries. Res. Commun. Chem. Pathol. Pharmacol. 1985; 47: 323-32.
22. Schwemmer M, Bassenge E. New approaches to overcome tolerance to nitrates. Cardiovasc. Drugs Ther. 2003; 17: 159-73.
23. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72: 248-54.
24. Saldeen T, Li D, Mehta JL. Differential effects of α- and γ-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J. Am. Coll. Cardiol. 1999; 34: 1208-15.
25. Lassila M, Santisteban J, Finckenberg P et al. Vascular changes in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. J. Physiol. Pharmacol. 2001; 52: 21-38.
26. Megson IL. Nitric oxide donor drugs. Drug Future 2000; 25: 701-15.
27. Tavares P, Reis F, Fontes-Ribeiro CA, Teixeira F. Cardiovascular effects of CsA in an experimental animal model. Rev. Port. Cardiol. 2002; 21: 141-55.
28. Martin A, Wong KS, Li M, Turner SW, Whitworth JA. Cyclosporin hypertension in the Wistar rat: Role of uninephrectomy. Clin. Exp. Pharmacol. Physiol. 1994; 21: 287-92.
29. Azzadin A, Mysliwiec J, Wollny T, Mysliwiec M, Buczko W. Serotonin is involved in the pathogenesis of hypertension developing during erythropoietin treatment in uremic rats. Thromb. Res. 1995; 77: 217-24.
30. Hervé P, Launay JM, Scrobohaci ML et al. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 1995; 99: 249-54.
31. Stroes ES, Hijmering M, Zandvoort M, Rabelink TJ, Faassen EE. Origin of superoxide production by nitric oxide synthases. FEBS Lett. 1998; 438: 161-4.
32. Wever RMF, Luscher TF, Cosentino F, Rabelink T. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-12.
33. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: Relationship to endothelial dysfunction, clinical and genetic risk factors. J. Physiol. Pharmacol. 2002; 53: 515-24.
34. Miller Jr FJ, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ. Res. 1998; 82: 1298-305.
35. Goodwin DC, Landino LM, Marnett LJ. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J. 1999; 13: 1121-36.
36. Brown AS, Moro MA, Masse JM, Cramer EM, Radomski M, Darley-Usmar VM. Nitric oxide-dependent and -independent effects on human platelets treated with peroxynitrite. Cardiovasc. Res. 1998; 40: 380-8.
37. Graham A, Hogg N, Kalyanaraman B, O'Leary V, Darley-Usmar V, Moncada S. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett. 1993; 330: 181-5.
38. Zou MH, Ulrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett. 1996; 382: 101-4.
39. Zou MH, Martin C, Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol. Chem. 1997; 378: 707-13.
40. Hink U, Oelze M, Kolb P et al. Role of peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J. Am. Coll. Cardiol. 2003; 42: 1826-34.